Company: MDCXW
Filing Date: 2025-07-14
Form Type: 424B3
Source: 0001062993-25-012774
Chunk: 5

Company: Medicus Pharma Ltd.
Filing Date: 2025-07-14
Form: 424B3
Chunk 5
---
File No. 333-287582), which has been filed by the Company in accordance with its requirements under the SEPA. This report shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Item 9.01. Financial Statements and Exhibits. (d) Exhibits.

| Exhibit 
 No.     | Description                                                                  |
| 4.1     | Form of New Warrant                                                          |
| 10.1    | Form of Warrant Inducement Agreement                                         |
| 104.1   | Cover Page Interactive Data File (embedded within the inline XBRL document). |

Forward-Looking Statements

Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the closing of the Company's issuance of the New Warrants and the timing thereof, the Company's aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the Antev transaction, including the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company's plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe